Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer

被引:41
|
作者
Asuthkar, Swapna [1 ]
Stepanova, Victoria [4 ]
Lebedeva, Tatiana [4 ]
Holterman, AiXuan L. [2 ]
Estes, Norman [2 ]
Cines, Douglas B. [4 ]
Rao, Jasti S. [1 ]
Gondi, Christopher S. [3 ]
机构
[1] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA
[2] Univ Illinois, Coll Med Peoria, Dept Surg, Peoria, IL 61605 USA
[3] Univ Illinois, Coll Med Peoria, Dept Med, Peoria, IL 61605 USA
[4] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-STROMAL INTERACTIONS; GLIOMA-CELL INVASION; DOWN-REGULATION; RECEPTOR UPAR; SIDE POPULATION; ANTISENSE UPAR; HAIRPIN RNA; EXPRESSION; GROWTH;
D O I
10.1091/mbc.E12-04-0306
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is almost always lethal. One of the underlying reasons for this lethality is believed to be the presence of cancer stem cells (CSC), which impart chemoresistance and promote recurrence, but the mechanisms responsible are unclear. Recently the poor prognosis of PDAC has been correlated with increased expression of urokinase plasminogen activator (uPA). In the present study we examine the role of uPA in the generation of PDAC CSC. We observe a subset of cells identifiable as a side population (SP) when sorted by flow cytometry of MIA PaCa-2 and PANC-1 pancreatic cancer cells that possess the properties of CSC. A large fraction of these SP cells are CD44 and CD24 positive, are gemcitabine resistant, possess sphere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness. Increased tumorigenicity and gemcitabine resistance decrease after suppression of uPA. We observe that uPA interacts directly with transcription factors LIM homeobox-2 (Lhx2), homeobox transcription factor A5 (HOXA5), and Hey to possibly promote cancer stemness. uPA regulates Lhx2 expression by suppressing expression of miR-124 and p53 expression by repressing its promoter by inactivating HOXA5. These results demonstrate that regulation of gene transcription by uPA contributes to cancer stemness and clinical lethality.
引用
收藏
页码:2620 / 2632
页数:13
相关论文
共 50 条
  • [1] Identification of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) as therapeutic targets for pancreatic cancer.
    Della Croce, K
    Han, H
    Beroza, P
    Bearss, DJ
    von Hoff, DD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3668S - 3668S
  • [2] Circulating levels of urokinase-type plasminogen activator (uPA) in breast and pancreatic cancer patients
    Hamer, PJ
    Marx, JH
    Leitzel, K
    Ali, S
    Clarke, L
    Demers, L
    Harvey, HA
    Linnartz, R
    Lipton, A
    Mietlowski, W
    Carney, WP
    CLINICAL CHEMISTRY, 2005, 51 : A53 - A54
  • [3] UROKINASE PLASMINOGEN ACTIVATOR (UPA) AND ATHEROSCLEROSIS
    Fuhrman, B.
    Khateeb, J.
    Lati, Y.
    Aviram, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 63 - 64
  • [4] UROKINASE PLASMINOGEN ACTIVATOR (UPA) PROVOKES
    Fuhrman, B.
    Khateeb, J.
    Gantman, A.
    Aviram, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 143 - 143
  • [5] ImmunoPET of urokinase plasminogen activator (uPA) system: broad applicability in cancer imaging
    Yang, Dongzhi
    Severin, Gregory
    Dougherty, Casey
    Chen, Daiqin
    Mazar, Andrew
    Hong, Hao
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [6] IN VIVO PHARMACOKINETICS OF RADIOIODINATED UROKINASE PLASMINOGEN ACTIVATOR (UPA) INHIBITORS FOR IMAGING METASTATIC CANCER
    Berghhofer, P.
    Greguric, I.
    Shepherd, R.
    Katsifis, A.
    Ranson, M.
    Vine, K.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 9 - 10
  • [7] Role of Pancreatic Stellate Cells in Pancreatic Cancer: The Urokinase Plasminogen Activator System
    Fiala-Beer, E.
    Xu, Z.
    Phillips, P.
    Yang, L.
    Goldstein, D.
    Pirola, R.
    Wilson, J.
    Apte, M.
    PANCREAS, 2010, 39 (08) : 1320 - 1320
  • [8] Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression
    Hosen, S. M. Z.
    Haar, J.
    Xu, Z.
    Perera, C.
    Mekapogu, A. R.
    Pang, T. C. Y.
    Pothula, S.
    Goldstein, D.
    Pirola, R.
    Wilson, J.
    Buckley, B. J.
    Ranson, M.
    Apte, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 25 - 26
  • [9] Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer
    Iwata, Takehiro
    Kimura, Shoji
    Abufaraj, Mohammad
    Janisch, Florian
    Parizi, Mehdi Kardoust
    Haitel, Andrea
    Rink, Micheal
    Roupret, Morgan
    Fajkovic, Harun
    Seebacher, Veronica
    Nyirady, Peter
    Karakiewicz, Pierre I.
    Enikeev, Dmitry
    Rapoport, Leonid M.
    Nasu, Yasutomo
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (10) : 774 - 783
  • [10] Expression of urokinase-type plasminogen activator (uPA) and its regulators in breast cancer.
    Dublin, EA
    Barnes, DM
    Patel, NK
    Liebmann, R
    Hanby, AM
    JOURNAL OF PATHOLOGY, 2000, 190 : 15A - 15A